Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 7 of 16.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2007-000502-70 Sponsor Protocol Number: CAMN107ADE01 Start Date*: 2007-12-10
    Sponsor Name:Technical University of Munich
    Full Title: An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia
    Medical condition: To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014383-18 Sponsor Protocol Number: CRAD001CDE21T Start Date*: 2010-08-12
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer
    Medical condition: Germ cell tumor, metastatic, relapsed or refractory
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004538-14 Sponsor Protocol Number: TACTOR-2013 Start Date*: 2014-07-30
    Sponsor Name:Azienda Ospedaliera Universitaria Integrata Verona
    Full Title: Identification of a specific systemic transcriptome able to differentiate patients with renal transplantation in chronic treatment with tacrolimus from those with mTOR inhibitors.
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006980-35 Sponsor Protocol Number: PROTECT Start Date*: 2009-01-20
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-...
    Medical condition: Heart transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019315 Heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004607-11 Sponsor Protocol Number: Start Date*: 2006-02-23
    Sponsor Name:Hopital Erasme
    Full Title: Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft fu...
    Medical condition: “De novo” renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000404-28 Sponsor Protocol Number: CRAD001ANO05 Start Date*: 2016-07-20
    Sponsor Name:Novartis Norge AS
    Full Title: 5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) Title of the original SCHEDULE study: A controlled ran...
    Medical condition: Heart transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10019314 Heart transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006729-15 Sponsor Protocol Number: IGG-GIFA-001 Start Date*: 2008-11-25
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLO...
    Medical condition: pediatric patient after kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023439 Kidney transplant rejection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004745-28 Sponsor Protocol Number: V.1.1 Start Date*: 2008-09-04
    Sponsor Name:Medizinische Universität Wien, KIM III, Abteilung für Nephrologie
    Full Title: Certican (Everolimus®) against Cytomegalovirus Disease in Renal Transplant Patients
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007507-83 Sponsor Protocol Number: CRAD001AIT12 Start Date*: 2009-03-18
    Sponsor Name:NOVARTIS FARMA
    Full Title: Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label stud...
    Medical condition: Recipients of a de novo kidney transplant.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000882-11 Sponsor Protocol Number: NEORAD Start Date*: 2011-08-16
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: A comparison of blood and tissue biomarkers before and after nephrectomy in the firstline setting with everolimus in patients with locally advanced or metastatic renal cell carcinoma
    Medical condition: locally advanced or metastatic renal cell carcinoma - 1st line
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019683-37 Sponsor Protocol Number: ONC-2010-001 Start Date*: 2011-01-21
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
    Medical condition: Chemotherapy pre-treated thymoma and thymic carcinoma patients who have had at least one prior platinum-containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056296 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005939-78 Sponsor Protocol Number: C-II-008 Start Date*: 2012-06-25
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV
    Full Title: A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study)
    Medical condition: metastatic renal cell carcinoma (mRCC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022589-29 Sponsor Protocol Number: EP-TSC-624 Start Date*: 2011-03-22
    Sponsor Name:University of Oxford
    Full Title: Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer
    Medical condition: Renal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023422-20 Sponsor Protocol Number: GETNE1003 Start Date*: 2011-01-26
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Estudio en fase II de everolimus, un inhibidor mTOR (de formulación oral), junto con OcteotrideLAR®, en pacientes adultos con tumores neuroendocrinos gastrointestinales avanzados no funcionales y b...
    Medical condition: Tumores neuroendocrinos gastrointestinales
    Disease: Version SOC Term Classification Code Term Level
    13 10062476 Tumor neuroendocrino LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002133-22 Sponsor Protocol Number: C31005 Start Date*: 2016-05-29
    Sponsor Name:Millenium Pharmaceuticals, a wholly owned subsidiary of Takeda pharmaceutical Company Limited
    Full Title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advan...
    Medical condition: metastatic clear-cell renal cell carcinoma (mccRCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000517-36 Sponsor Protocol Number: CRAD001H2401 Start Date*: 2005-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-b...
    Medical condition: maintenance of liver transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) ES (Completed) IT (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002090-21 Sponsor Protocol Number: IM103177 Start Date*: 2016-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression
    Medical condition: Maintenance of renal transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018174-54 Sponsor Protocol Number: CERL080A2423 Start Date*: 2010-07-01
    Sponsor Name:Novartis Services AG
    Full Title: MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a C...
    Medical condition: de novo transplant recipients of Expanded Criteria Donor (ECD) kidneys
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LV (Prematurely Ended) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003656-40 Sponsor Protocol Number: PCYC-1128-CA Start Date*: 2016-02-17
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
    Medical condition: Metastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-001102-31 Sponsor Protocol Number: FG-506-02-41 Start Date*: 2005-07-08
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transpla...
    Medical condition: Stable, adult kidney transplant recipients (≥ 6 months post transplant) who are currently treated with Prograf®/MMF(CellCept®) or Prograf®/Mycophenolate Sodium(Myfortic®) with or without steroids w...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10014646 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:42:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA